BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36756391)

  • 1. Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients.
    Priambada D; Thohar Arifin M; Saputro A; Muzakka A; Karlowee V; Sadhana U; Bakhtiar Y; Prihastomo KT; Risdianto A; Brotoarianto HK; Andar E; Muttaqin Z
    Int J Gen Med; 2023; 16():393-403. PubMed ID: 36756391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
    Malueka RG; Dwianingsih EK; Bayuangga HF; Panggabean AS; Argo IW; Donurizki AD; Shaleh S; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2287-2295. PubMed ID: 32856857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco.
    Squalli Houssaini A; Lamrabet S; Senhaji N; Sekal M; Nshizirungu JP; Mahfoudi H; Elfakir S; Karkouri M; Bennis S
    Cureus; 2024 Mar; 16(3):e56361. PubMed ID: 38633919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma.
    Panambur CB; Ramamoorthy S; Srinivas BH; Jinkala SR; Verma SK; Sasidharan GM
    Int J Clin Exp Pathol; 2024; 17(1):13-21. PubMed ID: 38322173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gliomas - An experience based on molecular markers.
    Sarma S; Khonglah Y; Mishra J; Kakati A; Phukan P
    J Family Med Prim Care; 2021 Mar; 10(3):1341-1346. PubMed ID: 34041176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
    Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
    Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
    Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
    Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
    Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
    Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study.
    Anand N; Husain N; Varshney R; Malhotra KP; Kaif M
    J Carcinog; 2021; 20():20. PubMed ID: 34729052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.